A Phase 1 interventional study of D-2570 and Placebo in Healthy, sponsored by InventisBio Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-10.
Sponsored by InventisBio Co., Ltd · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, double-blind, placebo-controlled single and multiple ascending dose and food effect study on PK. Subjects in the SAD and MAD study take the drug under fasting conditions, while those in the food effect (FE) study are required to take the drug under fasting or fed conditions according to the protocol.
InventisBio Co., Ltd is the lead sponsor of 34 studies on the registry; 11 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
To assess the safety and tolerability of single, multiple doses and food effect trial of D-2570 tablets and Placebo in healthy subjects.
Drug: D-2570 · Drug: Placebo
To characterize the pharmacokinetics (PK) of single, multiple doses of D-2570 tablets and Placebo in healthy subjects.
Drug: D-2570 · Drug: Placebo
To assess the effects of D-2570 and Placebo on the QT/QTc interval in healthy subjects.
Drug: D-2570 · Drug: Placebo
To assess the effects of multiple doses D-2570 and Placebo on serum IL-17A in healthy subjects.
Drug: D-2570 · Drug: Placebo
To assess the effects of regular and high-fat on the pharmacokinetics of D-2570 tablets.
Drug: D-2570
To evaluate the relative bioavailability among health benefits of D-2570 tablets (9 mg specification) and D-2570 tablets (3 mg specification)
Drug: D-2570
D-2570 is a novel inhibitor targeting the TYK2 pseudokinase domain, which can inhibit the release of inflammatory factors and participate in immune regulation. D-2570 is being developed as a potential oral therapeutic drug for patients with psoriasis, ulcerative colitis, SLE, and other conditions.
A placebo refers to a tablet that has no therapeutic effect on medication.
Incidence of adverse events
Incidence of adverse events
Time frame: During the procedure
Result of vital signs
Test of resting blood pressure.
Time frame: During the procedure
Result of vital signs
Test of resting heart pulse.
Time frame: During the procedure
Result of vital signs
Test of respiratory rate.
Time frame: During the procedure
Result of vital signs
Test of body temperature.
Time frame: During the procedure
Result of physical examination
Test of height (meters)
Time frame: During the procedure
Result of physical examination
Test of weight (kilograms)
Time frame: During the procedure
Result of electrocardiogram
Test of beats per minute
Time frame: During the procedure
Result of electrocardiogram
Test of RR Interva
Time frame: During the procedure
Result of electrocardiogram
Test of PR Interva
Time frame: During the procedure
Result of electrocardiogram
Test of QRS Interva
Time frame: During the procedure
Result of electrocardiogram
Test of QT Interva
Time frame: During the procedure
Result of electrocardiogram
Test of QTcF msec
Time frame: During the procedure
Result of PK endpoints
Tmax
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
Tmax
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
Tmax
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
Cmax
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
Cmax
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
Cmax
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
t1/2
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
t1/2
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
t1/2
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
MRT
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
MRT
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
MRT
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
AUC0-∞
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
AUC0-∞
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
AUC0-∞
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
AUC0-t
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
AUC0-t
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
AUC0-t
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
CL/F
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
CL/F
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
CL/F
Time frame: Day1 to Day7 for every cycle of group FE
Result of PK endpoints
Vz/F
Time frame: Day1 to Day7 of group SAD
Result of PK endpoints
Vz/F
Time frame: Day1 to Day13 of group MAD
Result of PK endpoints
Vz/F
Time frame: Day1 to Day7 for every cycle of group FE
Assessment of hematology test
Red blood cell count
Time frame: During the procedure
Assessment of hematology test
Hemoglobin measurement
Time frame: During the procedure
Assessment of hematology test
Hematocrit measurement
Time frame: During the procedure
Assessment of hematology test
Platelet count
Time frame: During the procedure
Assessment of hematology test
White blood cell count
Time frame: During the procedure
Assessment of hematology test
Lymphocyte count
Time frame: During the procedure
Assessment of hematology test
Neutrophil count
Time frame: During the procedure
Assessment of hematology test
Monocyte count
Time frame: During the procedure
Assessment of hematology test
Eosinophil count
Time frame: During the procedure
Assessment of hematology test
Basophil count
Time frame: During the procedure
Assessment of urinalysis test
pH measurement
Time frame: During the procedure
Assessment of urinalysis test
Protein detection
Time frame: During the procedure
Assessment of urinalysis test
White blood cells count
Time frame: During the procedure
Assessment of urinalysis test
Red blood cells count
Time frame: During the procedure
Assessment of urinalysis test
Glucose measurement
Time frame: During the procedure
Assessment of urinalysis test
Specific gravity measurement
Time frame: During the procedure
Assessment of coagulation parameters test
Thrombin time
Time frame: During the procedure
Assessment of coagulation parameters test
Partial thromboplastin time
Time frame: During the procedure
Assessment of coagulation parameters test
International normalized ratio
Time frame: During the procedure
Assessment of coagulation parameters test
Fibrinogen
Time frame: During the procedure
Assessment of blood biochemistry test
Sodium
Time frame: During the procedure
Assessment of blood biochemistry test
Potassium
Time frame: During the procedure
Assessment of blood biochemistry test
Calcium
Time frame: During the procedure
Assessment of blood biochemistry test
Chlorine
Time frame: During the procedure
Assessment of blood biochemistry test
Total protein
Time frame: During the procedure
Assessment of blood biochemistry test
Albumin
Time frame: During the procedure
Assessment of blood biochemistry test
Alkaline phosphatase
Time frame: During the procedure
Assessment of blood biochemistry test
Alanine aminotransferase
Time frame: During the procedure
Assessment of blood biochemistry test
Aspartate aminotransferase
Time frame: During the procedure
Assessment of blood biochemistry test
Direct bilirubin
Time frame: During the procedure
Assessment of blood biochemistry test
Indirect bilirubin
Time frame: During the procedure
Assessment of blood biochemistry test
Total bilirubin
Time frame: During the procedure
Assessment of blood biochemistry test
Gamma glutamyl transferase
Time frame: During the procedure
Assessment of blood biochemistry test
Uric acid
Time frame: During the procedure
Assessment of blood biochemistry test
Creatinine
Time frame: During the procedure
Assessment of blood biochemistry test
Creatine kinase
Time frame: During the procedure
Assessment of blood biochemistry test
Urea
Time frame: During the procedure
Assessment of blood biochemistry test
Glucose
Time frame: During the procedure
Assessment of blood biochemistry test
Total cholesterol
Time frame: During the procedure
Assessment of blood biochemistry test
Triglycerides
Time frame: During the procedure
Result of safety endpoint
Test of QT Interva.
Time frame: During the procedure
Result of safety endpoint
Test of QTc Interva.
Time frame: During the procedure
Result of PD endpoint
Test of serum IL-17A.
Time frame: Day1 of group SAD
Result of PD endpoint
Test of serum IL-17A.
Time frame: Day1 and Day7 of group MAD
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2024 to primary completion in Jun 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: D-2570